Ipamorelin is one of the cleanest and most selective growth hormone stimulants available in the research space. Rather than injecting growth hormone directly, it works by telling your pituitary gland to release more of your own. It does this by mimicking ghrelin — the hunger hormone — at a receptor in the pituitary called GHSR-1a. When that receptor gets activated, the pituitary responds with a pulse of growth hormone that looks and behaves much like your body's natural releases.
What sets ipamorelin apart from older growth hormone secretagogues like GHRP-6 and GHRP-2 is its selectivity. The older compounds caused significant rises in cortisol, prolactin, and ACTH alongside the GH pulse — which created side effects and limited their usefulness. Ipamorelin produces a strong GH pulse with virtually no effect on those other hormones. That cleaner profile is why it became the preferred compound in this class for most researchers and practitioners.
Results from ipamorelin use typically build slowly over 3–6 months. Users commonly report improvements in sleep quality, body composition (more muscle, less fat), skin and hair, recovery from training, and energy levels. Most of these effects are downstream consequences of higher growth hormone levels rather than direct actions of ipamorelin itself. It's frequently combined with CJC-1295, a GHRH analogue, because the two compounds work on different receptors and amplify each other's effect on GH output.
The regulatory picture in the US has changed. Ipamorelin was previously available through compounding pharmacies, but following FDA PCAC reviews in 2024–2025, it was removed from the 503A bulks list and production through compounding pharmacies is currently suspended. The science behind it is well-established; the access question depends on where you are and ongoing regulatory developments.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
Ipamorelin is well-characterised in animal models and early human pharmacology studies as a highly selective GH secretagogue; long-term efficacy and safety data in humans remain limited due to lack of completed Phase 3 trials, and its regulatory status in the US is currently uncertain following FDA compounding restrictions finalised through 2024–2025 PCAC review.
the before-bed dosing rationale makes physiological sense given how gh release is tied to slow-wave sleep. curious whether the research supports timing it right at sleep onset vs a couple of hours before. the fasted state requirement seems more important to get right — elevated insulin clearly blunts the response.
the selectivity profile is genuinely what sets this apart from ghrp-6. reading the original novo nordisk papers — ipamorelin was specifically engineered to avoid the cortisol and prolactin responses that made earlier ghrps messy. that's a meaningful pharmacological distinction, not just marketing.
the fda compounding situation changed things. it was widely available through compounding pharmacies for years and now it's not. does anyone know if the pcac review found a specific safety concern or was this more of a general tightening of the 503a list? trying to understand whether the regulatory pullback reflects new risk data or just policy.
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
GHRP-6 stands for Growth Hormone Releasing Peptide 6. It works by binding to the ghrelin receptor in the pitui…
Known commercially as Increlex (mecasermin) in its only FDA-approved form, IGF-1 is the hormone your body uses…